<DOC>
	<DOCNO>NCT00247975</DOCNO>
	<brief_summary>Breast cancer common afflict 1 9 North American woman . The treatment breast cancer often require use chemotherapy include `` anthracyclines '' . Anthracyclines damage heart result heart failure even death . Clinicians researcher continually seek method reduce toxic effect anthracycline treatment . L-carnitine substance produce naturally body required normal heart function . Animal study suggest L-carnitine protects heart effect anthracyclines , however verified human . This study assess potential role L-carnitine prevention anthracycline induce heart damage . The investigator enroll 144 patient study . Patients randomly assign L-carnitine therapy standard care ( L-carnitine therapy ) . Patients L-carnitine group receive oral intravenous L-carnitine prior anthracycline therapy . Patients undergo regular follow test assess heart function . The investigator believe patient treat L-carnitine benefit few complication associate anthracycline treatment .</brief_summary>
	<brief_title>Ability L-carnitine Prevent Heart Damage Breast Cancer Patients Receiving Anthracycline Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Female patient must histologically cytologically indicate breast cancer ( stage I , II , III ) eligible adjuvant anthracycline chemotherapy [ FEC100 ACTaxol ( paclitaxel ) every 21 day . HER2 negative HER2 positive breast cancer immunohistochemistry ( IHC3+ ) and/or fluorescent insitu hybridization . Eastern cooperative oncology group ( ECOG ) performance status = 0 , 1 , 2 Age ≥ 18 year old . Ability understand willingness sign write informed consent document . The effect Lcarnitine develop human fetus recommend therapeutic dose unknown . For reason , woman childbearing potential must agree use adequate contraception prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Patients evidence metastatic breast cancer . Resting LV ejection fraction &lt; 50 % . Patients receive previous anthracycline therapy contraindication anthracycline . Patients contraindication Lcarnitine therapy Dexrazoxane therapy time enrollment . Patients abnormal baseline bloodwork : hemoglobin ≤ 100 mg/L platelet ≤ 100 x 10^9/L white blood cell ≤ 4 x 10^9/L creatinine , AST , ALT , bilirubin &gt; 1.5 x upper normal limit Participation another randomize clinical trial . Patients significant cardiac disease ( previous myocardial infarction , congestive heart failure , hemodynamically significant valvular heart disease ) would limit compliance study requirement . Patients take medication may affect LV function ( bblockers , amiodarone , ACEinhibitors , calcium channel blocker , digoxin ) . Patients symptoms heart failure . Patients unable participate study require long term follow . Pregnant lactating woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>L-carnitine</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Anthracycline Cardiotoxicity</keyword>
	<keyword>Primary prevention</keyword>
	<keyword>Anthracycline induce cardiotoxicity</keyword>
	<keyword>Left Ventricular Ejection Fraction</keyword>
</DOC>